Kevatril (Granisetron)

Granisetron selectively antagonizes 5‑HT3 receptors located in the central nervous system and gastrointestinal tract. By preventing serotonin from binding to these receptors, it blocks the neural pathways that initiate nausea and vomiting, providing effective control of these symptoms in patients receiving emetogenic therapies.

The dosage of Kevatril is determined by the prescribing clinician based on the patient’s specific treatment protocol, type of chemotherapy or surgery, and individual health factors. Healthcare professionals calculate the appropriate intravenous dose and administration schedule according to established clinical guidelines.

The safety of granisetron in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Kevatril (granisetron) is a selective 5‑HT3 antagonist, offering a favorable side‑effect profile compared with some older agents like ondansetron, especially regarding cardiac safety. It provides comparable efficacy in preventing chemotherapy‑induced nausea and vomiting, but clinicians may choose based on patient tolerance, drug interactions and institutional protocols.

Kevatril should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Ensure the container remains sealed until use and handle with aseptic technique to maintain sterility for intravenous administration.

Kevatril is supplied as an intravenous solution and is administered by slow IV injection or infusion, as directed by the treating physician. The exact rate and duration depend on the clinical setting, such as pre‑medication before chemotherapy or postoperative care.

Serious risks include cardiac arrhythmias, severe hypotension, anaphylactic reactions, and rare cases of serotonin syndrome, especially when combined with other serotonergic drugs. Patients should be monitored for signs of these events, and immediate medical attention is required if they occur.

Kevatril is contraindicated in patients with known hypersensitivity to granisetron or any component of the formulation. Caution is advised for individuals with significant cardiac disease, prolonged QT interval, or those taking other QT‑prolonging medications, as they may be at higher risk for adverse cardiac events.